Mytelka Daniel S, Nagar Saurabh P, D'yachkova Yulia, La Elizabeth M, Kaye James A, Candrilli Sean D, Kasper Bernd, Lopez-Martin Jose Antonio, Lorenzo Maria
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA.
Sarcoma. 2018 Sep 12;2018:2020591. doi: 10.1155/2018/2020591. eCollection 2018.
To describe health care resource utilization and costs for patients with advanced soft tissue sarcoma (STS) in the United Kingdom (UK), Spain, Germany, and France.
Physicians abstracted data for adult patients with a diagnosis of advanced STS (other than Kaposi's sarcoma or gastrointestinal stromal tumor) who received ≥1 lines of systemic therapy. Health care resource utilization related to advanced STS treatment was recorded; associated costs were estimated by applying unit costs.
A total of 130 physicians provided data for 807 patients (UK: 199; Spain: 203; Germany: 204; and France: 201). The site of care during active treatment varied based on differences in the health care systems of these four countries. Total mean per-patient health care cost in the UK was £19,457; in Spain, €26,814; in Germany, €20,468; and in France, €24,368. Advanced STS-related systemic treatment costs were driven primarily by drug acquisition and administration costs. Treatment-related costs increased during later lines of therapy for all countries except France, where they decreased after first-line therapy. Pain control and antiemetics were the most common supportive care medications.
This study provides real-world data on resource utilization and estimated costs in advanced STS and could inform policymakers about treatment burden.
描述英国、西班牙、德国和法国晚期软组织肉瘤（STS）患者的医疗资源利用情况及成本。
医生提取了诊断为晚期STS（非卡波西肉瘤或胃肠道间质瘤）且接受≥1线全身治疗的成年患者的数据。记录与晚期STS治疗相关的医疗资源利用情况；通过应用单位成本估算相关成本。
共有130名医生为807名患者提供了数据（英国：199例；西班牙：203例；德国：204例；法国：201例）。积极治疗期间的护理地点因这四个国家医疗保健系统的差异而有所不同。英国每位患者的平均医疗保健总成本为19,457英镑；在西班牙为26,814欧元；在德国为20,468欧元；在法国为24,368欧元。晚期STS相关的全身治疗成本主要由药物采购和给药成本驱动。除法国外，所有国家后续治疗线的治疗相关成本均增加，法国在一线治疗后成本下降。疼痛控制和止吐药是最常见的支持性护理药物。
本研究提供了晚期STS资源利用和估计成本的真实世界数据，可为政策制定者提供有关治疗负担的信息。
